Cat. No. 2609
Chemical Name: 2-Methyl-5-[(4-methylphenyl)amino]-
Biological ActivityInhibitor of SETD8 protein lysine methyltransferase (PKMT) (IC50 = 0.5 μM); suppresses H4K20 monomethylation in vitro. Also inhibits cyclin-dependent kinase (CDK) 4 (IC50 = 6.0 μM at CDK4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Blum et al (2014) Small-molecule inhibitors of SETD8 with cellular activity. ASC.Chem.Biol. [Epub ahead of print] 9 2471. PMID: 25137013.
Ryu et al (2000) 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg.Med.Chem.Lett. 10 461. PMID: 10743948.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Ryuvidine include:
FitzGerald et al (2014) A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response. PLoS One 9 e98891. PMID: 24902048.
Do you know of a great paper that uses Ryuvidine from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ryuvidine, supplier, Cyclin-dependent, protein, kinase, 4, cdk4, inhibitors, SETD8, protein, lysine, methyltransferases, inhibits, SPS8I2, Tocris Bioscience, Lysine Methyltransferase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitorP-3FAX-Neu5Ac
Sialic acid analog; sialyltransferase inhibitorTolcapone
COMT inhibitor; also inhibits transthyretin aggregationJNJ DGAT2-A
DGAT2 inhibitorLLY 507
Potent SMYD2 inhibitor
October 30 - November 3, 2016
Boston, MA, USA